Meet Our Speaker

Professor Benjamin Kile is the Executive Director and CEO of the Garvan Institute of Medical Research. He is an internationally recognised medical researcher who has made significant contributions to the understanding of blood cells, cancer, and inflammatory disease. His work shed light on the mechanisms of programmed cell death, informing the development of the BH3 mimetics, a new class of cancer drugs approved by the FDA in 2016. Professor Kile has a distinguished research leadership background, having occupied senior roles at WEHI, Monash University, and the University of Adelaide. He made foundational contributions to the establishment of the National Drug Discovery Centre, the South Australian immunoGENomics Cancer Institute, and the Bragg Comprehensive Cancer Centre.